ALL PSYCHEDELIC AND PSYCHEDELIC STOCK NEWS

Interview: Dr. Deborah Nash, Ibogaine and Miami Based DemeRX.

Partnered with ATAI Life Sciences ATAI. Amazing Interview. "I said there's no way that you can take one dose of Ibogaine...

Psychedelic Marketing Tips: Adrian Morrison

The Absolute Champion of Internet Advertising, Adrian Morrison, makes a believer out of Jordan, which is saying everything! Why can’t this be...

Shark Tank’s Kevin Harrington Invests In Psychedelics Company Psycheceutical (BWVI). Forbes

Mike Zapolin, Kevein Harrington and CEO Chad Harman Another Shark Tank original has invested in the psychedelic industry.

Adding Psycheceutical Bioscience (BWVI) $0.14 to Watch List. (Ketamine.)

Above: Lamar Odom and Psychedelic Advocate Mike Zappy Zapolin. We’re Calling a Sector Bottom, and Psycheceutical (BWVI)...

Ketamine and Yale University

Depression is one of the most common and most debilitating mental health disorders, affecting some 17 million adults in the US. It...

Johns Hopkins Receives $20M From Roland R. Griffiths Ph.D. Professorship Fund For Psychedelic Research

John Hopkins Center for Psychedelic and Consciousness Research Johns Hopkins University academics just a got a boost in their funding thanks to...

Is ATAI Live Sciences (ATAI) $2.00, Finally Turning?

After Dropping 94% From Post IPO high from $19.45, a loss of exceeding $3 billion and change, ATAI is in the early...

PSYCHECEUTICAL TO CONDUCT THE FIRST EVER PHASE I AND II CLINICAL TRIALS OF A NOVEL KETAMINE TOPICAL CREAM TO TREAT PTSD

Psycheceutical ​​enters into agreement with iNGENū to conduct ​human ​clinical trials of NeuroDirect™ ketamine topical ​in Australia

The Kahner Global Cannabis & Psychedelics Investment Summit.

Kahner Global’s 8th annual Cannabis & Psychedelics Investment Summit  When:...

Awakn Life Sciences (AWKNF) $0.30 Announces Signing of Lease for Second Clinic in Norway.

Trondheim in central Norway will be the location of Awakn's 4th clinic LIVE QUOTE

Silo Pharma (SILO) Issues Letter to Shareholders

Silo Pharma Issues Letter to Shareholders Detailing Progress on Pipeline Assets Combining Traditional Therapeutics with Psychedelic Medicine LIVE QUOTE

Silo Pharma (SILO) $3.36 Achieves New Milestone for SP-26 Therapeutic -Initiates IND Enabling Study of Topical Ketamine Formulation

View Post ENGLEWOOD CLIFFS, NJ, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage...

Silo Pharma (SILO) Attends Dawson James Conference.

We watched an excellent presentation from management at the Dawson conference and starting our due diligence now....

KetaDash

Ketamine at Home Treatments
RESEARCH

Most Popular

Interview: MAPS Founder Rick Doblin and Clearmind Medicine (CMND) CEO, Adi Zuloff-Shani.

INTRO VIDEO https://youtu.be/-RQikn6O3qw?si=o_IBy9yTlmfNNvky Join Clearmind Medicine CEO, Adi Zuloff-Shani,...

1000 Days Without Alcohol: Here’s What Happened

No..we didn't give up drinking - at least not yet. But we RUMinate about it from time to time. At a dinner...

Startup Ketamine Clinic ‘Being Health’ Raises $5.4 Million

This startup is opening a mental health clinic that offers ketamine therapy. BusinessInsider got an exclusive look at the pitch deck it...

LARGE CAP PSYCHEDELIC STOCKS

PSYCHEDELIC FUNDS AND ETFS